A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neoplasm Metastasis|Colorectal Neoplasms|Breast Cancer
Interventions: DRUG: Prexasertib|DRUG: Cisplatin|DRUG: Cetuximab|DRUG: G-CSF|DRUG: Pemetrexed|DRUG: Fluorouracil|DRUG: LY3023414|DRUG: Leucovorin
Sponsor: Eli Lilly and Company